These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 9225270

  • 1. WAY100635-induced augmentation of the 5-HT-elevating action of citalopram: relative importance of the dose of the 5-HT1A (auto)receptor blocker versus that of the 5-HT reuptake inhibitor.
    Hjorth S, Westlin D, Bengtsson HJ.
    Neuropharmacology; 1997; 36(4-5):461-5. PubMed ID: 9225270
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT1A receptor antagonists in the dorsal raphe pathway: role of somatodendritic autoreceptors.
    Romero L, Artigas F.
    J Neurochem; 1997 Jun; 68(6):2593-603. PubMed ID: 9166757
    [Abstract] [Full Text] [Related]

  • 12. (-)-Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine.
    Hjorth S.
    Eur J Pharmacol; 1996 May 15; 303(3):183-6. PubMed ID: 8813565
    [Abstract] [Full Text] [Related]

  • 13. Lack of 5-HT1A autoreceptor desensitization following chronic citalopram treatment, as determined by in vivo microdialysis.
    Hjorth S, Auerbach SB.
    Neuropharmacology; 1994 May 15; 33(3-4):331-4. PubMed ID: 7984270
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Further evidence for the importance of 5-HT1A autoreceptors in the action of selective serotonin reuptake inhibitors.
    Hjorth S, Auerbach SB.
    Eur J Pharmacol; 1994 Aug 01; 260(2-3):251-5. PubMed ID: 7988652
    [Abstract] [Full Text] [Related]

  • 16. Differential effect of local infusion of serotonin reuptake inhibitors in the raphe versus forebrain and the role of depolarization-induced release in increased extracellular serotonin.
    Tao R, Ma Z, Auerbach SB.
    J Pharmacol Exp Ther; 2000 Aug 01; 294(2):571-9. PubMed ID: 10900234
    [Abstract] [Full Text] [Related]

  • 17. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.
    Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, Hagan JJ, Middlemiss DN, Dawson LA.
    Eur J Pharmacol; 2005 Mar 07; 510(1-2):49-57. PubMed ID: 15740724
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Role of 5-HT1A receptors in the effects of acute chronic fluoxetine on extracellular serotonin in the frontal cortex.
    Invernizzi R, Bramante M, Samanin R.
    Pharmacol Biochem Behav; 1996 May 07; 54(1):143-7. PubMed ID: 8728551
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.